Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Guidant Corporation's shareholders have overwhelmingly voted in favor of the company's agreement to be acquired by Johnson & Johnson. Guidant has revealed that the acquisition price could differ from the announced $76 per share.
Subscribe to our email newsletter
The agreement, which was announced on December 15, 2004, remains subject to European and US regulatory review, as well as other customary closing conditions.
The terms of the agreement provide for a collar that, under certain circumstances, could value the acquisition price at either more or less than the announced acquisition price of $76 per share.
Ronald Dollens, president and CEO of Guidant Corporation, commented, “Guidant’s strong innovative and entrepreneurial culture provides a foundation for an excellent strategic fit with Johnson & Johnson. We firmly believe this business combination offers an unprecedented breadth of capabilities and resources that will accelerate the growth of new therapies and technologies, benefiting millions of patients around the world.”